JP2015501634A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501634A5 JP2015501634A5 JP2014540054A JP2014540054A JP2015501634A5 JP 2015501634 A5 JP2015501634 A5 JP 2015501634A5 JP 2014540054 A JP2014540054 A JP 2014540054A JP 2014540054 A JP2014540054 A JP 2014540054A JP 2015501634 A5 JP2015501634 A5 JP 2015501634A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- seq
- subject
- cell death
- dsrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 7
- 125000002652 ribonucleotide group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 108091081021 Sense strand Proteins 0.000 claims 4
- 230000000692 anti-sense effect Effects 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 210000002569 neuron Anatomy 0.000 claims 4
- 230000004112 neuroprotection Effects 0.000 claims 4
- 230000001720 vestibular Effects 0.000 claims 3
- 108091028664 Ribonucleotide Proteins 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 210000000609 ganglia Anatomy 0.000 claims 2
- 230000016273 neuron death Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000002336 ribonucleotide Substances 0.000 claims 2
- CKTSBUTUHBMZGZ-CHKWXVPMSA-N 4-amino-1-[(2s,4r,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 CKTSBUTUHBMZGZ-CHKWXVPMSA-N 0.000 claims 1
- 101150044146 CASP2 gene Proteins 0.000 claims 1
- 102100032616 Caspase-2 Human genes 0.000 claims 1
- 230000005788 Cochlea function Effects 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 208000003098 Ganglion Cysts Diseases 0.000 claims 1
- 101000867612 Homo sapiens Caspase-2 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 208000005400 Synovial Cyst Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003221 ear drop Substances 0.000 claims 1
- 210000003027 ear inner Anatomy 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000001323 spiral ganglion Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161554982P | 2011-11-03 | 2011-11-03 | |
| US61/554,982 | 2011-11-03 | ||
| US201261663627P | 2012-06-25 | 2012-06-25 | |
| US61/663,627 | 2012-06-25 | ||
| PCT/US2012/062894 WO2013067076A2 (en) | 2011-11-03 | 2012-11-01 | Methods and compositions for neuroprotection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501634A JP2015501634A (ja) | 2015-01-19 |
| JP2015501634A5 true JP2015501634A5 (https=) | 2015-12-17 |
| JP6118331B2 JP6118331B2 (ja) | 2017-04-19 |
Family
ID=47436166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014540054A Expired - Fee Related JP6118331B2 (ja) | 2011-11-03 | 2012-11-01 | 神経保護のための方法および組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9422560B2 (https=) |
| EP (1) | EP2773758B1 (https=) |
| JP (1) | JP6118331B2 (https=) |
| KR (1) | KR101970034B1 (https=) |
| CN (1) | CN103917647B (https=) |
| AU (1) | AU2012332517B9 (https=) |
| BR (1) | BR112014010769B1 (https=) |
| CA (1) | CA2851296C (https=) |
| IL (1) | IL232085B (https=) |
| MX (1) | MX356814B (https=) |
| SG (1) | SG11201401648RA (https=) |
| WO (1) | WO2013067076A2 (https=) |
| ZA (1) | ZA201403281B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201804960RA (en) * | 2013-12-12 | 2018-07-30 | Alnylam Pharmaceuticals Inc | Complement component irna compositions and methods of use thereof |
| CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| SG11202002940QA (en) | 2017-11-01 | 2020-04-29 | Alnylam Pharmaceuticals Inc | Complement component c3 irna compositions and methods of use thereof |
| WO2021081026A1 (en) | 2019-10-22 | 2021-04-29 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| WO2021237344A1 (en) * | 2020-05-25 | 2021-12-02 | Wilfrid Laurier University | Compositions and methods of inducing rnai or type i ifn in ifn competent cells and uses thereof |
| CN118302525A (zh) | 2021-10-29 | 2024-07-05 | 阿尔尼拉姆医药品有限公司 | 补体因子B（CFB）iRNA组合物及其使用方法 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5270030A (en) | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| JP3131222B2 (ja) | 1991-12-24 | 2001-01-31 | アイシス・ファーマシューティカルス・インコーポレーテッド | ギャップを有する２′修飾オリゴヌクレオチド |
| EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US20050032067A1 (en) | 2002-11-05 | 2005-02-10 | Prakash Thazha P. | Non-phosphorous-linked oligomeric compounds and their use in gene modulation |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| AR013269A1 (es) | 1997-08-04 | 2000-12-13 | Scras | Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AR020078A1 (es) | 1998-05-26 | 2002-04-10 | Syngenta Participations Ag | Metodo para alterar la expresion de un gen objetivo en una celula de planta |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| ES2234563T5 (es) | 1999-02-12 | 2018-01-17 | Daiichi Sankyo Company, Limited | Nuevos análogos de nucleósidos y oligonucleótidos |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| ATE443765T1 (de) | 2003-03-21 | 2009-10-15 | Santaris Pharma As | Analoga kurzer interferierender rna (sirna) |
| EP1602926A1 (en) | 2004-06-04 | 2005-12-07 | University of Geneva | Novel means and methods for the treatment of hearing loss and phantom hearing |
| EP2319925B1 (en) | 2004-08-16 | 2018-07-25 | Quark Pharmaceuticals, Inc. | Therapeutic uses of inhibitors of RTP801 |
| WO2006047842A2 (en) | 2004-11-08 | 2006-05-11 | K.U. Leuven Research And Development | Modified nucleosides for rna interference |
| US7825099B2 (en) | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
| EP1989307B1 (en) | 2006-02-08 | 2012-08-08 | Quark Pharmaceuticals, Inc. | NOVEL TANDEM siRNAS |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| US7872119B2 (en) * | 2007-02-26 | 2011-01-18 | Quark Pharmaceuticals, Inc. | Inhibitors of RTP801 and their use in disease treatment |
| WO2009001359A2 (en) | 2007-06-27 | 2008-12-31 | Quark Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of pro-apoptotic genes |
| RU2487716C2 (ru) | 2007-10-03 | 2013-07-20 | Кварк Фармасьютикалс, Инк. | Новые структуры малых интерферирующих рнк (sirna) |
| EP2242854A4 (en) | 2008-01-15 | 2012-08-15 | Quark Pharmaceuticals Inc | COMPOUNDS AND USES THEREOF |
| CA2718765A1 (en) | 2008-03-20 | 2009-09-24 | Quark Pharmaceuticals, Inc. | Novel sirna compounds for inhibiting rtp801 |
| WO2009147684A2 (en) | 2008-06-06 | 2009-12-10 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
| CA2962219C (en) | 2008-10-22 | 2020-08-25 | Quark Pharmaceuticals, Inc. | Methods for treating eye disorders |
| AU2010324658A1 (en) | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
| EP2862929B1 (en) | 2009-12-09 | 2017-09-06 | Quark Pharmaceuticals, Inc. | Compositions and methods for treating diseases, disorders or injury of the CNS |
| WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
| CN103097534B (zh) | 2010-06-24 | 2017-07-28 | 夸克制药公司 | 针对rhoa的双链rna化合物及其用途 |
-
2012
- 2012-11-01 AU AU2012332517A patent/AU2012332517B9/en not_active Ceased
- 2012-11-01 CN CN201280054213.1A patent/CN103917647B/zh not_active Expired - Fee Related
- 2012-11-01 EP EP12806730.3A patent/EP2773758B1/en not_active Not-in-force
- 2012-11-01 US US14/354,596 patent/US9422560B2/en not_active Expired - Fee Related
- 2012-11-01 MX MX2014005424A patent/MX356814B/es active IP Right Grant
- 2012-11-01 CA CA2851296A patent/CA2851296C/en not_active Expired - Fee Related
- 2012-11-01 SG SG11201401648RA patent/SG11201401648RA/en unknown
- 2012-11-01 KR KR1020147010978A patent/KR101970034B1/ko not_active Expired - Fee Related
- 2012-11-01 JP JP2014540054A patent/JP6118331B2/ja not_active Expired - Fee Related
- 2012-11-01 WO PCT/US2012/062894 patent/WO2013067076A2/en not_active Ceased
- 2012-11-01 BR BR112014010769-6A patent/BR112014010769B1/pt not_active IP Right Cessation
-
2014
- 2014-04-10 IL IL232085A patent/IL232085B/en active IP Right Grant
- 2014-05-08 ZA ZA2014/03281A patent/ZA201403281B/en unknown
-
2016
- 2016-08-04 US US15/228,174 patent/US9738896B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015501634A5 (https=) | ||
| ES2873350T3 (es) | Composiciones de ARN interferente asimétrico y usos de las mismas | |
| Brites | Regulatory function of microRNAs in microglia | |
| JP2011522036A5 (https=) | ||
| Chen et al. | Implication of miRNAs for inflammatory bowel disease treatment: Systematic review | |
| JP6234370B2 (ja) | 神経変性障害におけるマイクロｒｎａ | |
| JP2016506240A5 (https=) | ||
| ES2905257T3 (es) | Métodos y composiciones para la inhibición específica de alfa-1 antitripsina mediante ARN bicatenario | |
| JP2014097072A5 (https=) | ||
| JP2016513976A5 (https=) | ||
| JP6431480B2 (ja) | アルツハイマー病の治療および診断のためのビオチン複合体 | |
| Chen et al. | Nucleic acid-based therapeutics for pulmonary diseases | |
| SI2929031T1 (en) | PCSK9 IRNA assemblies and procedures for their use | |
| NZ624712A (en) | Compositions and methods for modulation of smn2 splicing in a subject | |
| HRP20201200T1 (hr) | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK | |
| JP2015516989A5 (https=) | ||
| JP2013226147A5 (https=) | ||
| SI2999785T1 (en) | SERPINA1 IRNA assemblies and procedures for their use | |
| de Fougerolles et al. | siRNA and the lung: research tool or therapeutic drug? | |
| Jamwal et al. | Gene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives | |
| EP2885008A1 (en) | Compositions and methods for treating peripheral arterial disease | |
| JP2016533190A5 (https=) | ||
| HRP20211525T1 (hr) | Molekule sirna specifične za notch 1 | |
| Bao et al. | Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophy | |
| JP2010265270A5 (https=) |